European Journal of Clinical Pharmacology

, Volume 39, Issue 3, pp 281–285 | Cite as

Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma

  • B. J. Lipworth
  • R. A. Clark
  • D. P. Dhillon
  • J. B. D. Palmer
  • D. G. McDevitt


The purpose of the present study was to compare the efficacy and systemic effects of 4 mg and 8 mg doses of salbutamol controlled release (SCR) after single dosing and at steady state in patients with asthma. Fifteen asthmatic patients (Age 36 y, FEV1 85% predicted) were given SCR 4 mg and 8 mg twice daily for 7 days in a randomised double-blind cross-over design, with at least 7 days washout between treatments.

There were no differences between the bronchodilator effects of 4 mg and 8 mg doses. There was no evidence of tolerance to the bronchodilator effects after chronic dosing. Morning and evening PEFR measurements also showed improvements during treatment with SCR 4 mg and SCR 8 mg, although there were no differences between the two formulations. Both doses of SCR caused significant objective tremor responses which were maintained after chronic dosing. The 8 mg dose produced a larger tremor response after single dosing, but not at steady-state. Subjective tremor occurred in 7 patients with SCR 8 mg, and in 2 patients with SCR 4 mg. There were no cardiac arrhythmias on Holter ECG monitoring.

These results suggest that the 8 mg dose of SCR was no more effective than the 4 mg formulation, and was associated with more systemic adverse effects.

Key words

salbutamol asthma beta-adrenoceptor controlled release formulation adverse effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Crompton GK (1982) Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis 63 [Suppl 119]: 101–104Google Scholar
  2. 2.
    Watson JM, Richens A (1974) The effects of salbutamol and terbutaline on physiological tremor, bronchial tone and heart rate. Br J Clin Pharmacol 1: 223–227Google Scholar
  3. 3.
    Jenne JW, Valcarenghi G, Druz WS, Starkey PW, Yu C, Shaughnessy TK (1986) Comparison of tremor responses to orally administered albuterol and terbutaline. Am Rev Respir Dis 134: 708–713Google Scholar
  4. 4.
    Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22: 587–593Google Scholar
  5. 5.
    Maeson FP, Smeets JJ (1986) Comparison of a controlled release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur J Clin Pharmacol 31: 431–436Google Scholar
  6. 6.
    Theeuwes F (1975) Elementary osmotic pump. J Pharm Sci 64: 1987–1991Google Scholar
  7. 7.
    Lipworth BJ, Clark RA, Dhillon DP, Charter MK, Palmer JBD, McDevitt DG (1989) Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled release in patients with bronchial asthma. Eur J Clin Pharmacol 37: 49–52Google Scholar
  8. 8.
    Cotes JE (1979) Lung function: assessment and application in medicine. 4th ed. Blackwell, OxfordGoogle Scholar
  9. 9.
    American Thoracic Society (1987) Standardisation of spirometry — 1987 update. Am Rev Respir Dis 136: 1285–1298Google Scholar
  10. 10.
    Lipworth BJ, McDevitt DG (1989) Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol 36: 239–245Google Scholar
  11. 11.
    Larsson S, Svedmyr N (1977) Bronchodilating effect and side effects of beta-adrenoceptor stimulation by different modes of administration (tablets, metered aerosol and combinations thereof). Am Rev Resp Dis 116: 861–869Google Scholar
  12. 12.
    Tsanakas JN, Bannister OH, Baxter P (1988) Tachyphylaxis does not occur after longterm administration of salbutamol controlled release. Eur Respir J 1 [Suppl 2]: 202sGoogle Scholar
  13. 13.
    Nielson NH, Weeke B, Ostlerer L, Wilkinson P, Kay A, Williams I, Ng SH, Wootars EFM, Beumer HM (1988) Salbutamol controlled release (Volmax) — A comparison with standard salbutamol tablets (ST) in the treatment of chronic obstructive airway disease (COAD). Eur Respir J 1 [Suppl 2]: 306sGoogle Scholar
  14. 14.
    Nelson HS, Raine D Jr, Doner DH, Posey CW (1977) Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis 16: 871–878Google Scholar
  15. 15.
    Jenne JW, Thomas TW, Strickland RD, Wall FJ (1977) Sensitivity of beta-responses during therapy with a long acting beta-2 preparation. J Allergy Clin Immunol 59: 383–390Google Scholar
  16. 16.
    Plummer AL (1978) The development of drug tolerance to beta-2 adrenergic agents. Chest 73 [Suppl]: 949–957Google Scholar
  17. 17.
    Lipworth BJ, Clark RA, Dhillon DP, Moreland TA, Struthers AD, Clark GA, McDevitt DG (1989) Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol 37: 567–571Google Scholar
  18. 18.
    Milroy R, Carter R, Carlyle DL, Boyd G (1990) Clinical and pharmacological study of a novel controlled release preparation of salbutamol. Br J Clin Pharmacol 29: 578–580Google Scholar
  19. 19.
    Dahl R (1988) A multicentre trial of salbutamol controlled release tablets (volmax) and standard salbutamol tablets (ventolin) in the management of asthma and chronic bronchitis. Eur Respir J 1 [Suppl 2]: 306sGoogle Scholar
  20. 20.
    Callaghan B, Ryan W, Hagstad H, Tegner K, Kotaniemi J (1986) A multicentre study of a new controlled-release formulation of salbutamol (salbutamol CR) compared with a titrated dose of slow-release theophylline (theodur) in the treatment of chronic obstructive airways disease. Bull Eur Physiopathol Respir 22 [Suppl 8]: 1115Google Scholar
  21. 21.
    Britton M (1988) A multicentre comparison of 8 mg salbutamol controlled release (SCR) tablets b. d. versus theophylline slow release tablets (300 mg) b. d. in control of reversible airways obstruction. Eur Respir J 1 [Suppl 2]: 197sGoogle Scholar
  22. 22.
    Creemers JPHM (1988) A multicentre comparative study of salbutamol controlled release (Volmax) and sustained-release theophylline (Theodur) in the control of nocturnal asthma. Eur Respir J 1 [Suppl 2]: 333sGoogle Scholar
  23. 23.
    Moore-GillonJ (1988) Volmax (salbutamol CR 8 mg) in the management of nocturnal asthma: a placebo controlled study. Eur Respir J 1 [Suppl 2]: 306sGoogle Scholar
  24. 24.
    Davies RJ, Ferguson H, Heldman MJ, Ollier S (1988) Oral controlled release albuterol: its effect in asthmatic symptoms and bronchial hyperresponsiveness. Am Rev Respir Dis 137 [Suppl]: 32Google Scholar
  25. 25.
    Larsson S, Svedmyr N, Thiringer G (1977) Lack of bronchial beta-adrenoceptor resistance in asthmatics during long-term treatment with terbutaline. J Allergy Clin Immunol 59: 93–100Google Scholar
  26. 26.
    Bengtsson B, Fagerstrom PO (1988) Extrapulmonary effects of terbutaline during prolonged administration. Clin Pharmacol Ther 31: 726–732Google Scholar
  27. 27.
    Lipworth BJ, Struthers AD, McDevitt DG (1989) Tachyphylaxis to systemic but not airways responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 140: 586–592Google Scholar
  28. 28.
    Al-Hillawi AH, Hayward R, Johnson NM (1984) Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma. Br Med J 288: 367Google Scholar
  29. 29.
    Mettaver B, Rouleau JC, Burgess JH (1985) Detrimental arrythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 109: 840–847Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • B. J. Lipworth
    • 1
    • 2
  • R. A. Clark
    • 2
  • D. P. Dhillon
    • 2
  • J. B. D. Palmer
    • 3
  • D. G. McDevitt
    • 1
  1. 1.Department of Clinical PharmacologyNinewells Hospital and Medical SchoolDundeeUK
  2. 2.Department of Thoracic MedicineKing's Cross HospitalDundeeUK
  3. 3.Glaxo Group ResearchGreenfordUK

Personalised recommendations